Nexa AB (40M)
XFRA XFRA Primary Summary
Nexa AB (40M) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Nexa AB ever had a stock split?
Nexa AB Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Mr. David Westberg CEO | XFRA Exchange | SE0007074166 ISIN |
| Sweden Country | 13 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Nanexa AB (publ) is a nanotechnology drug delivery company that leverages advanced nanobased platforms for the delivery of pharmaceuticals. Founded in 2007 and based in Uppsala, Sweden, the company has focused its efforts on the development and operation of its proprietary PharmaShell system. This system utilizes atomic layer deposition technology to enhance the delivery mechanisms of various drugs. Nanexa’s innovative approach aims to improve therapeutic outcomes for patients suffering from a range of serious medical conditions, including myelodysplastic Syndrome, Acute Myeloid Leukemia, multiple myeloma, and type 2 diabetes.
Products and Services
- PharmaShell
This is Nanexa’s flagship nanobased drug delivery platform that employs atomic layer deposition technology. PharmaShell is designed to optimize the delivery and efficacy of pharmaceuticals by enhancing their release profiles, stability, and patient compliance. It stands at the core of Nanexa’s product offerings, showcasing the potential of nanotechnology in transforming drug delivery.
- NEX-18
NEX-18 is a developmental stage product that encapsulates the capabilities of the PharmaShell platform. It targets myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML), two forms of cancer affecting the bone marrow and blood. Through NEX-18, Nanexa aims to deliver more effective treatments for these life-threatening diseases.
- NEX-20
With a focus on treating multiple myeloma, a cancer of plasma cells, NEX-20 represents another application of the PharmaShell technology. This product endeavors to provide a new means of combating a complex cancer by optimizing drug delivery mechanisms, potentially leading to improved therapeutic outcomes for patients.
- NEX-22
NEX-22 is tailor-made for the treatment of type 2 diabetes, a prevalent chronic condition worldwide. By leveraging the PharmaShell platform, NEX-22 aims to improve the efficiency of diabetes medications, enhancing patient quality of life and managing the disease more effectively.
